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F Casellas, F Guarner, M Antolin, R Rodriguez, A Salas, J-R Malagelada Abstract The mucosal release of inflammatory mediators is enhanced in active inflammatory bowel disease. This study examines whether leukotriene C4 production occurs in apparently unaffected segments of the gut. The intraluminal release of leukotriene C4 was determined by jejunal perfusion in seven healthy controls, in nine patients with chronic ulcerative colitis, and in 13 patients with Crohn's disease (six with ileal disease, and seven with only colonic). All patients were in clinical remission and none of them had evidence of jejunal involvement. Mild intraluminal irritation with a 2*5 mmol/l deoxycholic acid solution was induced to stimulate local inflammatory mechanisms. The release of DNA (a marker of mucosal desquamation) and prostaglandin E2 (PGE2) was simultaneously measured. Jejunal release of DNA was higher in Crohn's disease patients than in ulcerative colitis or healthy controls. Basal release of PGE2 was similar in the three groups of patients. Basal release of leukotriene C4 was considerably enhanced, however, in Crohn's disease patients compared with healthy controls. In ulcerative colitis patients, basal leukotriene C4 release was non-significantly different from controls. Bile acid perfusion stimulated PGE2, leukotriene C4, and DNA release in all groups studied, but leukotriene C4 release was significantly higher in Crohn's disease patients. It is concluded that in inactive Crohn's disease there is an enhanced intraluminal release of leukotriene C4 in apparently unaffected segments of proximal small bowel, which may reflect findamental changes in the function of the gut mucosal barrier.
(Gut 1994; 35: Jejunal net water flux was similar in the four groups studied (mean (SEM)) (2-2 (0-6) ml/min in controls, 2 2 (1 3) in chronic ulcerative colitis, 2 7 (0 3) in colonic Crohn's disease, and 2 0 (0 3) in ileal Crohn's disease, p=NS). Perfusion with deoxycholic acid induced water secretion, increasing net water flux similarly in controls (4-6 (1 -0) ml/min, p<001) and all disease groups (chronic ulcerative colitis: 3-4 (0 5), colonic Crohn's disease: 3 7 (0 6), ileal Crohn's disease: 2-9 (0 2), p<0 05).
Basal mean DNA release in chronic ulcerative colitis patients was similar to that seen in healthy subjects. In both colonic and ileal Crohn's disease, however, basal DNA release was higher than in controls (see Fig 1) . As a consequence of the irritative effect, deoxycholic acid perfusion induced mucosal cellular desquamation, increasing luminal DNA release in healthy controls and, similarly, in chronic ulcerative colitis and Crohn's disease patients (Table I) .
LUMINAL LEUKOTRIENE C4 RELEASE Leukotriene C4 was released into the jejunal lumen in measurable quantities in all subjects studied (Fig 2) . Basal mean release ofleukotriene C4 in healthy controls was below 20 ng/min. 
0O
Chronic ulcerative colitis patients showed a trend towards higher basal leukotriene C4 release than controls (43 (16) ng/min), but the difference was not significant largely because of three individual chronic ulcerative colitis patients with a high basal leukotriene C4 release: one patient with widespread colitis and two with left sided colitis. They had been in remission for 2 to 56 weeks, and treated with low doses of methylprednisolone (two patients) or salazopirine (one patient). From the six chronic ulcerative colitis patients with low leukotriene C4 release, two had not received any drug treatment and four were receiving low dose methylprednisolone. In contrast with leukotrienes that are proinflammatory eicosanoids, PGE2 exerts a protective effect on intestinal mucosa against noxious agents. Thus, it has been shown that exogenous PGE2 protects the small bowel from indomethacin induced ulcerationeM and also protects the colon from a variety of damaing agents including ethanol, indomethacn, and tnrnitrobenzenesulphonic acid.3'3 In addition, rabbits immunised with PGE2 that produce circulating antibodies develop ulcers both in the stomach and small intestine, suggesting that endogenous PGE2 also plays an active part in the defence of intestinal mucosa.u More importandy, it seems that one mechanism for PGE2 mediated intestinal mucosal protection could be inhibition of parietal leukotriene production.-Mu Our results would thus suggest that in Crohn's disease the PGE2 mediated intestnal mucosal protection is preserved (normal PGE2 generation) but that the defence balance is upset by the predomiance of proinammatory leukotriene C4 production. Why intestinal leukotriene C4 production is higher in Crohn's disease than in ulcerative colitis cannot be answered by our studies. Crohn's disease patients exhibit higher basal and luminal leukotriene C4 outputs after irritation than chrnic ulcerative colitis patients. The different magnitude may reflect greater underlying inflammatory activity in Cro's diseas (a of ubiquitous gastintesinal involvement) or could reflect a more fimdamental discrepancy in pathogenic mechanism between these two forms ofinflammatory bowel di.
In conclusion, our results show that the intraluminal release ofleukotrieneCand DNA in the unaffected jejunum of ptients with quiescent Cohn's disease is enhanced and that its capacty to increase in resonse to mucosal irrtation is preserved. These findings suggest that in Crohn's disease even when the disase is clinically inactive there is a widespread and sustined activation of intestinal pnflammatory medcansms. These changs may represent fundamental changsp in the function of the gut mucosal barrier. 
